What is Cornerstone Robotics?
Cornerstone Robotics (CSR) operates at the intersection of high-precision engineering and clinical medicine. As a leading innovator in surgical robotics, the company develops sophisticated systems designed to enhance the efficiency and accessibility of surgical procedures worldwide. By integrating multidisciplinary expertise—ranging from robotics engineering to clinical practice—CSR addresses the growing demand for minimally invasive and high-precision surgical interventions. The company's strategic footprint, spanning major innovation centers in Asia and Europe, allows it to leverage diverse talent pools and regulatory environments to maintain a competitive edge in the medical device market.
How much funding has Cornerstone Robotics raised?
Cornerstone Robotics has raised a total of $348.3M across 3 funding rounds:
Series B
$78.3M
Series C
$70M
Other Financing Round
$200M
Series B (2021): $78.3M with participation from New World, Meituan, Eli Lilly, and Gaorong Capital
Series C (2025): $70M led by EQT, Alpha JWC Ventures, Qiming Venture Partners, eGarden, and ITVF - Innovation and Technology Venture Fund
Other Financing Round (2025): $200M supported by Gaorong Capital and Qiming Venture Partners
Key Investors in Cornerstone Robotics
Gaorong Capital
Gaorong Capital is a China-based venture capital firm that specializes in identifying and supporting high-growth technology companies through strategic investment.
Qiming Venture Partners
Qiming Venture Partners is a prominent firm focused on innovative companies across healthcare and technology, providing strategic guidance and industry resources to foster long-term growth.
Eli Lilly
Eli Lilly and Company is a global biopharmaceutical leader dedicated to research-driven innovation in prescription medicines, including oncology and immunology.
What's next for Cornerstone Robotics?
With the recent infusion of capital, Cornerstone Robotics is well-positioned to scale its operational infrastructure and expand its clinical footprint. The strategic focus will likely shift toward the commercialization of next-generation robotic systems and the deepening of its research and development capabilities. As the company matures, it will likely prioritize regulatory approvals in new territories and the expansion of its global service network. The continued support from high-profile investors suggests a long-term commitment to establishing CSR as a standard-bearer in the surgical robotics industry, potentially setting the stage for future market consolidation or strategic partnerships within the broader biopharmaceutical and medical technology ecosystems.
See full Cornerstone Robotics company page
